Myovant Sciences is a biotech company that develops new treatments for infertility in women and prostate cancer in men. The company's product capabilities and help continue to deliver innovative therapies addressing unmet patient needs in prostate cancer and women’s health. Myovant Sciences was established in 2016 and is based in Brisbane, California.

Myovant Sciences is dedicated to transforming the lives of women and men by developing innovative healthcare solutions in the fields of reproductive health and endocrine disorders. Their core mission is to advance science and medicine to address unmet medical needs, with a focus on improving patient outcomes and quality of life. By fostering a culture of collaboration and excellence, Myovant Sciences aims to create a lasting impact on the healthcare landscape and empower individuals to take control of their health.

• Well-being and safety of employees is a top priority
• Myovant Sciences strongly encourages employees to get vaccinated, if eligible
• Not requiring employees to be fully vaccinated against COVID-19 as a condition of employment

• Patient focus: Myovant Sciences is dedicated to improving the lives of patients, putting their needs at the forefront of everything they do.
• Innovation: Myovant Sciences encourages creativity and innovation, empowering employees to think outside the box and develop new solutions to complex problems.
• Collaboration: Collaboration is key to Myovant Sciences's success, fostering a culture of teamwork and open communication to achieve shared goals.
• Integrity: Myovant Sciences operates with the highest level of integrity, prioritizing ethical behavior and transparency in all aspects of the business.
• Diversity and inclusion: Myovant Sciences values diversity and inclusion, recognizing that a diverse workforce leads to better decision-making and a more inclusive workplace culture.